The Competition Council launched for public consultation the report on sector inquiry on pharma market
|
|
- Harry Lawson
- 6 years ago
- Views:
Transcription
1 The Competition Council launched for public consultation the report on sector inquiry on pharma market One of the conclusions of the sector inquiry on pharma sector carried out by the Competition Council is that the generic medicines, although are with 35% less expensive than the innovative ones, have not a significant market share even many years after they entered on the market. In the same time, the competition authority found that there are markets where, once the generic medicines appears, there increased the market share of other innovative medicines for which no generic equivalent exists yet. The conclusions of the sector inquiry are similar to those of the previous sector inquiry, concluded by the Competition Council in 2011 which showed that there is a high concentration of certain markets, mainly due to marketing of innovative medicines. The sector inquiry showed also that 57% of patients require a specific brand of medicines following the doctor recommendation, though in Romania, the active substance is specified on the prescription and only in exceptional circumstances the brand. The Competition Council identified as a possible cause of this behaviour the producer intensive promotion of innovative medicines. Thus, a company producing innovative medicines spends an average of 9% of its turnover for promotion activity while a company producing generic medicines allocates about 5%. 1
2 In 2014, the promotion and advertising expenditure made by medicines producers in Romania amounted approx. lei 362 million. As a result, the doctors recommend innovative medicines as they are influenced by the medicines producers by marketing, promotion and advertising activities: scientific congresses, meetings, promotional and advertising materials, sponsorships. The most involved medical specialties are family/general medicine physicians followed by cardiologists and internists. The Competition Council considers that doctors could be encouraged to prescribe generic medicines by receiving financial incentives in case they do not exceed a monthly budget and the savings to the budget could be used by doctors for other purposes such as internships. In case of referencing medicines, the patient pays the difference between the reference price (usually of the cheapest generic) and the price of sold medicines, depending on the degree of compensation. The analysis showed that, in most cases, the cheapest generic is missing from the market or is sold in small quantities. In this context, the Competition Council proposes the elimination from the compensation lists of the medicines that are marketed in insufficient quantities and are maintained just for reference price. Also, the Competition Council supports the limitation of marketing expenses for certain categories of activities, respectively a better definition of expenditure that can be made for each type of marketing or promotion activity. The competition authority also recommends an analysis on the possibility of setting a maximum amount that can be allocated to a prescribing physician in a year. At the same time, the analysis performed at pharmacies showed that patients are directed to certain pharmacies to purchase medicines. As a result, a very small number of pharmacies administrate a high amounts reimbursed at county level. For example, in Iasi, in September 2014, out of 386 pharmacies who delivered medicines included in national health programs, a single pharmacy reimbursed 69% out of total medicines released within the National Oncology Program. Within the National Transplant Program, a pharmacy reimbursed 43% of all medicines. 2
3 Thus, the Competition Council recommends the elimination of advantages that can be offered to doctors by representatives of pharmacies or distributors so that they, in turn, to distribute promotional coupons available only in some pharmacies. In this way, there will be a real competition between pharmacies, based on competitive prices and quality service. To motive distributors and pharmacies to sell inexpensive medicines a solution for it to become profitable is to apply a fixed amount per distribution service, respectively pharmacy. Also, in order distributors/ pharmacies not to sell or promote a particular medicine in the detriment of another, a possible solution would be to limit the discounts. Another practice is that the most distributors relate the delivery of medicines that are requested and well sold as mandatory to the acquisition of other medicines the pharmacy would not order if it is not forced. This tying sale affects cash-flow of pharmacies and their ability to compete effectively on the market. The Competition Council recommends the introduction in the Health Law of a provision that forbids tying sale (packages) in case of medicines distribution. Within the sector inquiry, the situation on missing medicines was also analysed and a certain percentage of exports for each of them were found. Therefore, the Competition Council recommends a more effective monitoring of the obligation of public service by ANMDM (the National Agency for Medicines and Medical Devices) at each level of the medicines supply chain, including the pharmacies. Thus, the producers must ensure, firstly, sufficient quantities to meet the national need, the distributors to supply mainly on domestic market, and to export only surpluses quantities. Also, to improve the availability of medicines, the competition authority recommended to distributors to supply all pharmacies, not just those integrated. At present, there are still vertically integrated pharmacies with a common management with the distributor, being possible to transfer the goods from the distributor to pharmacy without being charged. According to legislation, from 1 st of January 2017, the pharmacy and distributor must become separate entities and therefore are bound to have different management. In this way, there will not be possible anymore to export medicines that are in pharmacies and the possibility to appear counterfeit medicines will be reduced. 3
4 Also, the Competition Council considers necessary to develop a methodology to define more clearly the concept of public service. This would clarify the existing legal framework and would lead to behaviour self-assessment of companies who have this obligation by law. The Competition Council is working closely with ANMDM to identify causes of the lack of medicines on the market and to develop a new methodology for verifying the compliance with the public service obligation. In order the Romanian patients to have access to new, efficient medicines, the Competition Council recommended the inclusion of a medicine on the reimbursement lists once it received marketing authorization and price decision. As regards generic medicines, the Competition Council claims that their prices should not be affected permanently by the price of correspondent innovative medicines. The Competition Council considers that after the patent expired, there should be a genuine competition between innovative and generic medicines, including on price. In order to prevent price discrimination for medicines with the same active substance (International Non-proprietary Names - INN), the Competition Council recommends the same price for generic medicine and for innovative medicine that is no longer under patent Another conclusion of the Report is that not all producers have updated the medicine price according to regulations in force (Order 75/2009). Thus, the minimum amount collected in addition, in 2014, by producers, reached approx. lei 467 million (approx. Euro 103 million). As a result, total sales in Romania were higher and overcoming of the allocated budget for medicines was supported partly both by companies that have updated prices through the claw-back tax, and by patients through co-payment, depending on the degree of medicines compensation. According to legislation in force, the medicines price in CaNaMed (National Catalogue of prices for human use medicines with a prescription) is valid for a limited period, respectively a year, calculated from the date of the Ministry of Health s authorization and must be less or equal than the price of the same medicine from the list of 12 countries with which the comparison is made. Romania is also the reference country for medicine prices in other EU Member States. 4
5 Therefore, low prices in Romania could affect prices in other countries for which Romania is the reference country. A possible solution could be keeping the prices in Pricing Public Catalogue at higher level, which is a reference for other countries, while the reimbursement to be made at a lower price. The Competition Council considers that claw-back tax must be applied differently for generic medicines and for those that are not under patent anymore in comparison with new medicines that are more expensive and involves a fiscal effort. A lower claw-back tax for generics could keep them on the market. Given the changing of distribution systems implemented by certain producers lately, there was analysed the impact of DTP systems (direct-to-pharmacy) and restricted by distribution. Whatever the distribution system is, if the producer is dominant, the advantages at the pharmacy / hospital level and patient must be similar to those previously recorded and must be measurable at all levels: quality, service level, financial advantages and availability just the change of the distribution system not to be regarded as abuse of dominant position. In conclusion, the Competition Council does not recommend the use of a distribution system in the detriment of another, but will intervene on certain markets opening investigations in the event that there are clues on distortion of competition. In this context, the Competition Council opened an investigation on a possible abuse of dominant position of Novartis Pharma Services Romania SRL by implementing a pilot project for direct distribution to certain pharmacies, alongside with traditional distribution. During the investigation, there was carried out an unannounced inspection at the premises of Novartis Pharma Services Romania SRL. The gathered documents are under analysis of the Romanian competition authority according to specific investigation procedures. Also, the Competition Council analyses the possible violation of competition law by GSK Romania, through the implementation of a system of direct distribution to pharmacies. The Competition Council considers the pharmaceutical field as a priority and will continue to monitor the market to identify any malfunctions that may affect the competitive environment or the patient. 5
6 The sector inquiry report is launched for public consultation on the website of the Competition Council, The interested parties may submit comments on the report until July 1, 2016 to the address Innovative medicine is a brand new medicine protected by patent when launched on the market. Generic medicine contains the same active substance as innovative medicine but is not protected by patent anymore. June 2016 Press Office Tel.: 0372/129710; 021/ presa@consiliulconcurentei.ro 6
Global Forum on Competition
Unclassified DAF/COMP/GF/WD(2014)51 DAF/COMP/GF/WD(2014)51 Unclassified Organisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development 14-Feb-2014 English
More informationACCOUNTABILITY AND TRANSPARENCY IN PHARMA SUPPLY CHAIN 6/26/2018. Presentation to UN 2018 Public Service Forum. Richard Bergström External Lead Pharma
ACCOUNTABILITY AND TRANSPARENCY IN PHARMA SUPPLY CHAIN Presentation to UN 2018 Public Service Forum Richard Bergström External Lead Pharma Enabling trust 1 SICPA: GLOBAL ROLE Protection of 85+% world currency
More informationIntroduction to the Generic Drug Supply Chain and Key Considerations for Policymakers
Association for Accessible Medicines Introduction to the Generic Drug Supply Chain and Key Considerations for Policymakers Key Takeaways Generic drugs play an important role in the U.S. health care system,
More informationDrug Reimportation: Learning from the experience in Europe
1 24/02/2004 Drug Reimportation: Learning from the experience in Europe National Medicare Prescription Drug Congress Washington DC 27 February 2004 2 24/02/2004 Contents Differences between the US and
More informationPolicy principles for a competitive healthcare environment
Policy principles for a competitive healthcare environment Pharmaceutical Research and Development Industry Malta Association (PRIMA) PRIMA is an affiliate of the European Federation of Pharmaceutical
More informationRomania. Raluca Vasilescu Cabinet M Oproiu. Pharmaceutical Trademarks 2015/2016. A Global Guide
Romania Raluca Vasilescu Cabinet M Oproiu Pharmaceutical Trademarks 2015/2016 A Global Guide Romania Cabinet M Oproiu Author Raluca Vasilescu Selection, clearance and registration In Romania, pharmaceutical
More informationNew Cardinal Health (Post-Spin)
New Cardinal Health (Post-Spin) George Barrett Vice Chairman and Chief Executive Officer Healthcare Supply Chain Services and Chief Executive Officer Cardinal Health, Inc. (post-spin) January 14, 2009
More informationMEDICINES PRICES IN INDONESIA
MEDICINES PRICES IN INDONESIA Ms. Selma Siahaan Center for Health Services and Technology R&D National Institute of Health R&D Indonesia 14 June 2006 Geographic regions II IV III I Medicines Prices Survey
More informationUnderstanding How The Indian Pharmaceutical Industry Works Part 3
Understanding How The Indian Pharmaceutical Industry Works Part 3 Key Performance Indicators Pharmaceutical Sector Sales & Marketing Marketing always starts with the customer and ends with the customer
More informationPharmaceutical Pricing Policy Options. Andreas Seiter The World Bank June 2008
Pharmaceutical Pricing Policy Options Andreas Seiter The World Bank June 2008 Basic Definitions Manufacturer price COGS* plus profit margin Regulated price set as price ceiling or fixed price based on
More informationDeveloped Markets Italy,Portugal,Spain
Developed Markets Italy,Portugal,Spain Istanbul, 15 th June 2007 Hugo Carradinha Health Economics Affairs Manager Italy Current Market Share Italian Pharmaceutical Market Source: IMF data 03/07 Italy -
More informationPharmaceutical Trademarks
Published by Pharmaceutical Trademarks 2012 Hungary Contributing firm Third Edition Hungary Contributing firm Author Georgina Busku Selection, clearance and registration The following trademarks may enjoy
More informationNew Indications & Cross- Label Dispensing
New Indications & Cross- Label Dispensing Date: 11/11/2015 Position Paper Executive Summary Innovation is a continuous process, and appropriate incentives are needed to encourage development of the full
More informationFederal Register /Vol. 72, No. 136 /Tuesday, July 17, 2007 /
Federal Register /Vol. 72, No. 136 /Tuesday, July 17, 2007 / 447.504 Determination of AMP. (a) AMP means, with respect to a covered outpatient drug of a manufacturer (including those sold under an NDA
More informationSummary of Proposed USP General Chapter <1083> Good Distribution Practices Supply Chain Integrity 02/15/2012
Summary of Proposed USP General Chapter Good Distribution Practices Supply Chain Integrity 02/15/2012 This summary was prepared by the Rx-360 Monitoring and Reporting Working Group which tracks
More informationPromoting Medical Products Globally
Promoting Medical Products Globally Handbook of Pharma and MedTech Compliance PERU This publication is copyright. Apart from any fair dealing for the purpose of private study or research permitted under
More informationPHARMACEUTICAL PRICING & REIMBURSEMENT SYSTEM IN SPAIN
PHARMACEUTICAL PRICING & REIMBURSEMENT SYSTEM IN SPAIN PPRI Conference 29-30 September 2011, Vienna Piedad Ferré Pharmaceutical offer in Spain some features High coverage and rapid accessibility Pharmaceutical
More informationPromoting Medical Products Globally
Promoting Medical Products Globally Handbook of Pharma and MedTech Compliance Peru This publication is copyright. Apart from any fair dealing for the purpose of private study or research permitted under
More informationVisiongain. -v1531/ Publisher Sample
Visiongain http://www.marketresearch.com/visiongain -v1531/ Publisher Sample Phone: 800.298.5699 (US) or +1.240.747.3093 or +1.240.747.3093 (Int'l) Hours: Monday - Thursday: 5:30am - 6:30pm EST Fridays:
More informationFACTORS AFFECTING ON PHARMACEUTICAL PRODUCTS BRAND PROMOTIONS: A STUDY ON PROFESSIONAL ENDORSEMENT PERSPECTIVE
FACTORS AFFECTING ON PHARMACEUTICAL PRODUCTS BRAND PROMOTIONS: A STUDY ON PROFESSIONAL ENDORSEMENT PERSPECTIVE Sriwignarajaa, K. and Fernando, P.M.P. Department of Marketing Management, Faculty of Commerce
More informationImplementation of Pharmaceutical Policy Reform. Andreas Seiter Senior Health Specialist Access to Essential Medicine The World Bank
Implementation of Pharmaceutical Policy Reform Andreas Seiter Senior Health Specialist Access to Essential Medicine The World Bank Sector issues Critical sector for health outcomes Characterized by market
More informationApplication for registration certificate to operate a retail pharmacy 5, ,000.00
Appendix 3: Pharmaceutical Regulatory Authority Schedule of Fees, 2010 A. RETAIL / HOSPITAL PHARMACY FEE UNITS (1 fee Unit = K180) APPLICATION FEES (ZMK) 1 2 Application for registration certificate to
More informationTrends in Weighted Average Sales Prices for Prescription Drugs in Medicare Part B,
Trends in Weighted Average Sales Prices for Prescription Drugs in Medicare Part B, 2007-2017 December 2017 THE MORAN COMPANY 1 Trends in Estimated Average Sales Price for Prescription Drugs in Medicare
More informationRating Methodology by Sector. Pharmaceuticals
Last Updated: December 7, 2011 Rating Methodology by Sector Pharmaceuticals Pharmaceuticals are mainly categorized into ethical drugs, which are provided to patients by hospital pharmacies or by dispensing
More informationExcessive Pricing in Pharmaceutical Markets - Note by Denmark
Organisation for Economic Co-operation and Development DAF/COMP/WD(2018)104 DIRECTORATE FOR FINANCIAL AND ENTERPRISE AFFAIRS COMPETITION COMMITTEE English - Or. English 25 October 2018 Excessive Pricing
More informationGUIDELINES FOR REGISTRATION OF IMPORTERS AND FOR THE IMPORTATION OF MEDICINES AND RELATED PRODUCTS
MEDICINES CONTROL AGENCY 54 Kairaba Avenue, Pipeline, The Gambia. Tel.no. +220 4380632 GUIDELINES FOR REGISTRATION OF IMPORTERS AND FOR THE IMPORTATION OF MEDICINES AND RELATED PRODUCTS Document no: MCA/IMPG/2017/1
More informationChemically synthesized proteins referencing biological medicinal products
Chemically synthesized proteins referencing biological medicinal products A EuropaBio white paper Calling for: - Equal assessment transparency - Equal measures for traceability and adverse event reporting
More informationREPORT FROM THE COMMISSION TO THE COUNCIL AND THE EUROPEAN PARLIAMENT COMPETITION ENFORCEMENT IN THE PHARMACEUTICAL SECTOR ( )
EUROPEAN COMMISSION Brussels, 28.1.2019 COM(2019) 17 final REPORT FROM THE COMMISSION TO THE COUNCIL AND THE EUROPEAN PARLIAMENT COMPETITION ENFORCEMENT IN THE PHARMACEUTICAL SECTOR (2009-2017) European
More informationFULL TABLE OF CONTENTS AND CHARTS & GRAPHICS
PHARMACEUTICAL SALES MANAGEMENT SHARPENING CUSTOMER-CENTRIC STRATEGIES TO RESTORE ACCESS AND STRENGTHEN RELATIONSHIPS FULL TABLE OF CONTENTS AND CHARTS & GRAPHICS 1000 Park 40 Plaza, Suite 440 Durham,
More informationThe need for generic policies as part of health reform
The need for generic policies as part of health reform Richard Laing EMP/WHO for PPRI Conference Vienna September 30 th 2011 The US Generics Market reaches $107.5bn with growth four times higher than total
More informationSec Short title; finding. Sec Authority to assess and use drug fees. Sec Reauthorization; reporting requirements.
H.R. 2430, FDA Reauthorization Act of 2017 Section 1. Short Title. This Act may be cited as the FDA Reauthorization Act of 2017. Section 2. Table of Contents Table of Contents TITLE I: FEES RELATING TO
More informationMaximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS
Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS by Jan Nielsen, division president, Access & Patient Support Are You Asking the Right Questions? We ve all
More informationOperational Considerations for Transparency. September 2011
Operational Considerations for Transparency September 2011 Current Global Regulatory Trends Type of Regulations/ Guidance Company s obligations Scope Sanctions/ Penalties State Laws Promotional spend reporting
More informationLEVERAGING OUR BIOLOGICS EXPERTISE IN BIOSIMILARS SCOTT FORAKER VICE PRESIDENT AND GENERAL MANAGER, BIOSIMILARS
LEVERAGING OUR BIOLOGICS EXPERTISE IN BIOSIMILARS SCOTT FORAKER VICE PRESIDENT AND GENERAL MANAGER, BIOSIMILARS SAFE HARBOR STATEMENT This presentation contains forward-looking statements that are based
More informationCOUNTERFEIT MEDICINES IMPACT AND POTENTIAL SOLUTIONS
COUNTERFEIT MEDICINES IMPACT AND POTENTIAL SOLUTIONS October 2-3, 2012 The World Bank Innovative technologies to identify fake and substandard drugs in resource-limited settings: Supply chain related technologies
More informationPharmaceuticals in a Global Environment
Pharmaceuticals in a Global Environment The Story of Heartburn Anne Johnson, M.D. 100 University Dr. Long Beach, CA 90840 Lic No: 1234 DEA #: 98765 The Purple Pill Prilosec, 20 mg As needed for acid reflux
More informationWhite paper The Polish pharmaceutical market has undergone many changes as a result of the new Reimbursement Act
White paper The Polish pharmaceutical market has undergone many changes as a result of the new Reimbursement Act Published: July 2014 Author: Anantharaman Kavassery Viswanthan Anantharaman Kavassery Viswanathan
More informationBi Regional Consultation on Good Governance
Pharmaceutical Services Ministry of Health Malaysia GGM PROGRAMME IN MALAYSIA WHO Collaborating Centre For Regulatory Control of Pharmaceuticals Bi Regional Consultation on Good Governance 9 th November
More informationCompetition Enforcement in the Pharmaceutical Sector ( )
Report from the Commission to the Council and the European Parliament Competition Enforcement in the Pharmaceutical Sector (2009-2017) European competition authorities working together for affordable and
More informationHigh quality generics in pharmaceutical market
High quality generics in pharmaceutical market On 3 April the State Council released a new guideline on research, development and adaptation of generic medicine as part of China s healthcare system. Through
More informationGUIDE TO COMPETITION LAW FEBRUARY 2014
GUIDE TO COMPETITION LAW FEBRUARY 2014 GUIDE TO COMPETITION LAW 2 TABLE OF CONTENT 1 Introduction 3 1.1 Why did SMARTRAC develop this Guide to Competition Law 3 1.2 To whom this guide applies 3 1.3 What
More informationPharma R&D and Patents support Health Care & Economy
Pharma R&D and Patents support Health Care & Economy Konstantinos Μ. Frouzis President of SFEE, V.P & Gen. Manager of Novartis Hellas April 28 th, 2014 Intellectual Property Patents: The vehicle for innovation
More informationPrescription Drug Pricing. Page 1
Prescription Drug Pricing Page 1 Prescription Drugs As a Percent of Total National Health Expenditures, 1991-2014 12% 10% 8% 6% 4% 2% 0% 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
More informationIn the huge expanse of Asia, Singapore and
New Medical Device Regulation 16 February 2009 By Ames Gross In the huge expanse of Asia, Singapore and Hong Kong are small places. However, after Japan, they are among the most advanced medical markets
More informationPhRMA GUIDING PRINCIPLES DIRECT TO CONSUMER ADVERTISEMENTS ABOUT PRESCRIPTION MEDICINES
PhRMA GUIDING PRINCIPLES DIRECT TO CONSUMER ADVERTISEMENTS ABOUT PRESCRIPTION MEDICINES P hrma GUIDING PRINCIPLES DIRECT TO CONSUMER ADVERTISEMENTS ABOUT PRESCRIPTION MEDICINES PREAMBLE Given the progress
More informationEU Pharmaceutical law. André den
EU Pharmaceutical law André den Exter denexter@bmg.eur.nl @AndredenExter Outline Occasion EU Pharmaceutical law: regulating the pharmaceutical chain What is a Medicine? Clinical Trials Marketing Authorization
More informationWEDNESDAY, JANUARY 20 REGULAR CALENDAR
WEDNESDAY, JANUARY 20 REGULAR CALENDAR TRANSPORTATION HB 280, a committee to study placing medal decals on special number plates for veterans. OTP/A. Vote 15-0. HRA Analysis: As amended, this bill creates
More informationValue Based Pricing- New Concept
37 Review Article Value Based Pricing- New Concept Shwetlata Singh Department of Pharmaceutical Management, Delhi Institute of Pharmaceutical Sciences & Research, Delhi, India shweta.kul99@yahoo.com ABSTRACT
More informationEXAMINE THE BREAKDOWN OF FEES IN MANAGED MARKETS AND SPECIALTY PHARMACIES
EXAMINE THE BREAKDOWN OF FEES IN MANAGED MARKETS AND SPECIALTY PHARMACIES CBI 4TH ANNUAL FMV CONGRESS March 28, 2017 2017 HURON CONSULTING GROUP INC. SPEAKER INTRODUCTIONS John Moose, CPA, ABV Director
More informationThe White House s Drug Pricing Blueprint
Debevoise In Depth The White House s Drug Pricing Blueprint May 18, 2018 On May 11, 2018, the White House released the President s Blueprint to Lower Drug Prices (the Blueprint ). Because President Trump
More informationReal-Life Strategies for Account Managers to Help Grow Market Share
1 CMR Institute 2017. All Rights Reserved. Real-Life Strategies for Account Managers to Help Grow Market Share As an account manager, understanding your customers challenges including their performance
More informationHealth Products and Food Branch Inspectorate
Our Mandate: To promote good nutrition and informed use of drugs, food, medical devices and natural health products, and to maximize the safety and efficacy of drugs, food, natural health products, medical
More informationBRITISH GENERIC MANUFACTURERS ASSOCIATION
BRITISH GENERIC MANUFACTURERS ASSOCIATION Response by the British Generic Manufacturers Association (BGMA) to the Department of Health Consultation on Amendments to the Statutory Scheme to Control the
More informationTestimony of Molly Ventrelli Vice President, Regulatory Affairs Fresenius Kabi USA, LLC
Testimony of Molly Ventrelli Vice President, Regulatory Affairs Fresenius Kabi USA, LLC U.S. House of Representatives Energy and Commerce Committee Subcommittee on Health Subcommittee January 30, 2018
More informationCerpassRx Member Handbook
CerpassRx Member Handbook Welcome CerpassRx is pleased to administer your prescription benefit plan. About Us CerpassRx is an innovative Pharmacy Benefit Administrator that offers access to pharmacies
More informationYASHAJIT SAHA & ABHISHEK SHARMA, SUBJECT MATTER EXPERTS, RESEARCH & ANALYTICS ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN PHARMA.
YASHAJIT SAHA & ABHISHEK SHARMA, SUBJECT MATTER EXPERTS, RESEARCH & ANALYTICS ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN PHARMA wns wns ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN
More informationEnsuring Independence in CME Activities:
Ensuring Independence in CME Activities: Compliance Expectations of the ACCME s Standards for Commercial Support SM CME is Independent What is the practice-based problem we want to address? Why does the
More informationUS Pharmacy Benefit Management Market Report
US Pharmacy Benefit Management Market Report ----------------------------------------- 2014 Executive Summary In the US, Pharmacy Benefit Management (PBM) deals with the management of prescription drug
More informationE-Commerce of Healthcare Products in the EU
E-Commerce of Healthcare Products in the EU Dr. Ann-Christin Richter, LL.M. (Durham) Basel, 19 May 2017 Introduction (I) Growing importance of online sales (goods and services) Online sales turnover in
More informationARIKAYCE U.S. FDA Approval
S E P T E M B E R 2 8, 2 0 1 8 ARIKAYCE U.S. FDA Approval Forward Looking Statements This presentation contains forward-looking statements. "Forward-looking statements," as that term is defined in the
More informationUsing Your Prescription. Drug Program. Answers to important questions about retail pharmacy and mail order purchasing
Using Your Prescription Drug Program Answers to important questions about retail pharmacy and mail order purchasing Welcome! We know you re going to enjoy the many advantages of your prescription drug
More informationMedical Devices. LATVIA LAWIN Klavins & Slaidins
Medical Devices LATVIA LAWIN Klavins & Slaidins CONTACT INFORMATION Sarmis Spilbergs LAWIN Klavins & Slaidins Elizabetes 15, Riga, LV 1010, Latvia +371 67814848 sarmis.spilbergs@lawin.lv www.lawin.com
More informationHORIZON 2030 Executive Summary LPIA Workshop
HORIZON 2030 Executive Summary LPIA Workshop 30th September 2017 1 CONTENTS P 4 1.0 Introduction 1.1 The Event & Objectives 1.2 The Agenda & Presentations 1.3 The Attendance 2.0 The profession 2.1 Role
More informationForeign Affairs, Defence and Trade Select Committee Parliament Wellington. 24 March 2016
Foreign Affairs, Defence and Trade Select Committee Parliament Wellington 24 March 2016 Dear Committee Members, Our apologies for a delayed written submission (attached) on the International treaty examination
More informationBGMA Associate Membership
BGMA Associate Membership Making medicines affordable Promoting Innovation November 2011 GENERICS -THE FACTS Generic medicines meet the same standards of quality, safety and efficacy as originator brands.
More informationUnrealized Savings from the Misuse of REMS and Non-REMS Barriers. By Alex Brill
Unrealized Savings from the Misuse of REMS and Non-REMS Barriers By Alex Brill September 2018 EXECUTIVE SUMMARY Risk Evaluation and Mitigation Strategies (REMS) are drug safety programs required by the
More informationBiosimilars contracting in the NHS. Maggie Dolan Regional Pharmacy Procurement Specialist South East Coast
Biosimilars contracting in the NHS Maggie Dolan Regional Pharmacy Procurement Specialist South East Coast Aim Introduction Managing the Medicine Budget in the NHS The Biosimilar Medicine Challenges Questions
More informationCOST AND MANAGEMENT AUDIT. Paper-19. Syllabus Set-2. Answer of Postal test Paper. Set-2.
Paper-19 Syllabus-2016 Set-2 Answer of Postal test Paper Set-2 www.globalcma.in info@globalcma.in Q.1 A. Fill in Blanks 1. 1965 2. Committed 3. Optimum 4. Application of Cost Audit B. Tru or False 1. True.
More informationNews For Immediate Release
News For Immediate Release Contact: Gary Gatyas IMS Institute for Healthcare Informatics (610) 244-2600 ggatyas@us.imshealth.com IMS Study Forecasts Rebound in Global Spending on Medicines, Reaching Nearly
More informationPharmaceutical pricing, i reimbursement, Europe: an overview (I) Elias Mossialos and Reinhard Busse
Pharmaceutical pricing, i reimbursement, HTA and cost containment measures in Europe: an overview (I) Elias Mossialos and Reinhard Busse Policy issues in pharmaceutical markets Structure of the pharmaceutical
More informationPharmacophore 2011, Vol. 2 (6), ISSN Pharmacophore. (An International Research Journal)
Pharmacophore 2011, Vol. 2 (6), 271-275 ISSN 2229 5402 Pharmacophore (An International Research Journal) Available online at http://www.pharmacophorejournal.com/ Review Article A REVIEW: EXPLORING BRANDED
More informationEUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY
EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Health systems, medical products and innovation Medicines: policy, authorisation and monitoring STAMP 4/24 Record STAMP Commission Expert
More informationSummary of Medicines Plan
Summary of Medicines Plan Ministry of Public Health, Welfare and Sport Summary of Medicines Plan 1 Content Introduction 4 1 Accessibility of innovative medicines 5 Go to action 2 Tackle the high price
More informationReport of the Signatory Companies: Volume XII
2016 Introduction The Pharmaceutical Research and Manufacturers of America s (PhRMA) Guiding Principles on Direct-to-Consumer (DTC) Advertisements about Prescription Medicines ( PhRMA Guiding Principles
More informationADVANCING THE SINGLE MARKET FOR MEDICINES GIRP Position Paper
ADVANCING THE SINGLE MARKET FOR MEDICINES GIRP Position Paper 1. The Single Market The single internal European market was one of the primary stated purposes of the 1957 Treaty of Rome. The arrangements
More information1. Council conclusions on strengthening the balance in the pharmaceutical systems in the EU and its Member States
PRESS 17/6/2016 PRESS RELEASE Council of the European Union 1. Council conclusions on strengthening the balance in the pharmaceutical systems in the EU and its Member States "The Council of the European
More informationChapter. The Implications of Patent-Term Extension for Pharmaceuticals
Chapter The Implications of Patent-Term Extension for Pharmaceuticals Chapter 4 The Implications of Patent-Term Extension for Pharmaceuticals This chapter examines the possible impact of pharmaceutical
More informationThe Danish Generic Medicines Industry Association (IGL)
The Danish Generic Medicines Industry Association (IGL) comments on the concept paper on the delegated act for a unique identifier for medicinal products for human use, and its verification. The Danish
More informationSustainable Competition:
Sustainable Competition: the Magic Formula to Align Public Health and Business Objectives for Access Adrian van den Hoven Director General Medicines for Europe Medicines For Europe VISION Medicines for
More informationGuide to Wholesaling and Brokering of Medicinal Products for Human Use in Ireland
Guide to Wholesaling and Brokering of Medicinal Products for Human Use in Ireland IA-G0008-5 17 JUNE 2017 This guide does not purport to be an interpretation of law and/or regulations and is for guidance
More informationPharmaceutical Sector Governance in the Middle East and North Africa Region A Regional Review by the World Bank
Pharmaceutical Sector Governance in the Middle East and North Africa Region A Regional Review by the World Bank Presented at the Workshop on Governance of Pharmaceuticals in MENA Amman, Jordan June 6,
More informationPreparing for product launch
Preparing for product launch A Finance Perspective CBI Conference September 28, 2017 Today s presenters Today s presenters Susan Garfield Principal Advisory, Life Sciences EY Bill Roberts Partner Northeast
More informationTendering & Purchasing
Annapolis Valley Regional School Board Administrative Procedure AP 200.1 Tendering & Purchasing Department: Finance Section: Departments of Finance and Operations Table of Contents Section 1 Purpose and
More informationMedical Devices. LITHUANIA LAWIN Lideika, Petrauskas, Valiunas ir partneriai
Medical Devices LITHUANIA LAWIN Lideika, Petrauskas, Valiunas ir partneriai CONTACT INFORMATION Ruta Pumputiene LAWIN Lideika, Petrauskas, Valiunas ir partneriai Jogailos str. 9 / 1, LT-01116 Vilnius,
More informationPromoting Medical Products Globally
Promoting Medical Products Globally Handbook of Pharma and MedTech Compliance VENEZUELA This publication is copyright. Apart from any fair dealing for the purpose of private study or research permitted
More informationUPS Healthcare Supply Chain Vital Signs
UPS Study Executive September 2017 START 2017 UPS Survey 2017 United Parcel Service of America, Inc. 1 An industry growing more complex: managing competition, compliance and costs Pharmacies are grappling
More informationPharmaceutical law legal FramewOrK
Pharmaceutical law LEGAL FRAMEWORK 2015 CONTENTS: Hardly any area of law has such a direct connection to human health as pharmaceutical law. This fact requires fulfillment of detailed and strict conditions
More informationPromotional Tools Effect on Pharmaceuticals Marketing
Promotional Tools Effect on Pharmaceuticals Marketing Post Raj Pokharel 1* Abstract This paper shows the effect of promotional tools on pharmaceuticals marketing. The study is based on survey method using
More informationDrugs and Medical Devices Regulatory & Industry Overview
Drugs and Medical Devices Regulatory & Industry Overview Presented to: Vanderbilt University April 10, 2013 Charles N. (Chuck) Jolly cjolly@bakerdonelson.com Ph. 410.648.5004 or 914-924-0738 (cell) Industry
More informationImplementation of the safety features in medicinal products for human use
Circular published on the INFARMED I.P website in 4 th Sept.2017 Translation of the responsibility of APIFARMA (not official) Information Circular N. º 108/CD/100.20.200 Date: 01/09/1017 Subject: For:
More informationThe U.S. Wholesaler Market: Past, Present and Future
The U.S. Wholesaler Market: Past, Present and Future 2012 H. D. Smith National Sales & Management Conference August 8, 2012 John M. Gray President and CEO HDMA The History of HDMA 1876 2012 Exchange Hall,
More informationGUIDANCE FOR INDUSTRY. Questions and Answers
GUIDANCE FOR INDUSTRY Prescription Drug Marketing Act (PDMA) Requirements Questions and Answers U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and
More informationPharmaceutical Marketing. lecture Two Microenvironment Environment Lecturer: Enas Abu-Qudais
Pharmaceutical Marketing lecture Two Microenvironment Environment Lecturer: Enas Abu-Qudais Marketing Environment There are various factors/ forces, that directly or indirectly influence the organizations
More informationSTRATEGIC CASE STUDY FEBRUARY 2018 EXAM ANSWERS. Variant 5. The February 2018 exam can be viewed at
STRATEGIC CASE STUDY FEBRUARY 2018 EXAM ANSWERS Variant 5 The February 2018 exam can be viewed at These answers have been provided by CIMA for information purposes only. The answers created are indicative
More informationGirl Scouts of Central Texas Delegation of Authority Policy Reviewed and approved by GSCTX Finance Committee: March 21, 2017
Girl Scouts of Central Texas Delegation of Authority Policy Reviewed and approved by GSCTX Finance Committee: March 21, 2017 PURPOSE This Delegation of Authority Policy outlines limits of authority for
More informationA Guide to Competition Law
Behaviour in Competition A Guide to Competition Law RZ_ROC_Bro_Behaviour_Competition_e.indd 1 11.0.10 14:06 Behaviour in Competition RZ_ROC_Bro_Behaviour_Competition_e.indd 2 11.0.10 14:06 1 Contents I
More informationGS1 Turkey Yeliz Geriş. İTS -Turkish Pharmaceutical Track and Trace System
GS1 Turkey Yeliz Geriş İTS -Turkish Pharmaceutical Track and Trace System What is İTS? İTS-Pharmaceutical Track & Trace System Project Phases Implementation Timeline Objectives Scope Labeling Workflow
More informationQ Results & Acquisition of Tea Leaves Health
Q2 2015 Results & Acquisition of Tea Leaves Health Safe Harbor During the course of this presentation, we may make forward-looking statements, including statements regarding the company's future financial
More informationGIRP-IPF Study 2016 KEY FINDINGS EUROPEAN HEALTHCARE DISTRIBUTION ASSOCIATION GROUPEMENT INTERNATIONAL DE LA RÉPARTITION PHARMACEUTIQUE
GIRP-IPF Study 2016 KEY FINDINGS EUROPEAN HEALTHCARE DISTRIBUTION ASSOCIATION GROUPEMENT INTERNATIONAL DE LA RÉPARTITION PHARMACEUTIQUE The role of the pharmaceutical wholesale sector 2 ROLE OF PHARMACEUTICAL
More informationMaster of Business Administration Course Descriptions
Master of Business Administration Course Descriptions CORE COURSES MBAB 5P01 Accounting for Decision-Making I The functional basics of accounting for management and business decisions. Data collection,
More information